Predictors of survival in periampullary cancers following pancreaticoduodenectomy
- PMID: 20108122
- PMCID: PMC2861840
- DOI: 10.1245/s10434-009-0883-9
Predictors of survival in periampullary cancers following pancreaticoduodenectomy
Abstract
Background: Cancers of the ampulla of Vater, distal common bile duct, and pancreas are known to have dismal prognosis. It is often reported that ampullary cancers are less aggressive relative to the other periampullary carcinomas. We sought to evaluate predictors of survival for periampullary cancers following pancreaticoduodenectomy to identify biologic behavior.
Methods: We reviewed the records of all patients who underwent pancreaticoduodenectomy for periampullary carcinoma between 1992 and 2007 at the Ohio State University Medical Center. Demographics, treatment, and outcome/survival data were analyzed. Kaplan-Meier survival curves were created and compared by log-rank analysis. Multivariate analysis was undertaken using Cox proportional-hazards method.
Results: 346 consecutive periampullary malignancies (249 pancreatic cancers, 79 ampullary carcinomas, 18 extrahepatic cholangiocarcinomas) treated by pancreaticoduodenectomy were identified. Pancreatic cancer histology correlated with the shortest median survival (17.1 months), followed by cholangiocarcinoma (17.9 months) and ampullary carcinoma (44.3 months) (P < 0.001). Potential predictors of decreased survival on univariate analysis included site of origin, preoperative jaundice, microscopic positive margin, nodal metastasis, lymphovascular invasion, neural invasion, and poor differentiation. Only nodal metastasis (median 16.2 versus 29.9 months, P < 0.001) and neural invasion (median 17.7 versus 47.9 months, P < 0.00001) significantly predicted outcome on multivariate analysis.
Conclusions: Although ampullary cancers have the best prognosis overall, when controlled for tumor stage, only presence of neural invasion and nodal metastasis predict poor survival following pancreaticoduodenectomy. Biological behavior remains the most important prognostic indicator in periampullary cancers amenable to resection, regardless of site of origin.
Figures
Similar articles
-
Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma.BMC Cancer. 2008 Jun 11;8:170. doi: 10.1186/1471-2407-8-170. BMC Cancer. 2008. PMID: 18547417 Free PMC article.
-
Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?Ann Surg Oncol. 2013 Feb;20(2):430-9. doi: 10.1245/s10434-012-2603-0. Epub 2012 Sep 7. Ann Surg Oncol. 2013. PMID: 22956064
-
[Results of pancreaticoduodenectomy in the treatment of periampullary tumors].Rev Med Chil. 2011 Aug;139(8):1015-24. Epub 2011 Dec 20. Rev Med Chil. 2011. PMID: 22215331 Spanish.
-
Ampullary cancer: an overview.Am Soc Clin Oncol Educ Book. 2014:112-5. doi: 10.14694/EdBook_AM.2014.34.112. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857067 Free PMC article. Review.
-
Prognostic factors and benefits of adjuvant therapy for ampullary cancer following pancreatoduodenectomy: A systematic review and meta-analysis.Asian J Surg. 2020 Dec;43(12):1133-1141. doi: 10.1016/j.asjsur.2020.03.007. Epub 2020 Apr 2. Asian J Surg. 2020. PMID: 32249101
Cited by
-
Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage.Surg Endosc. 2015 Nov;29(11):3273-81. doi: 10.1007/s00464-015-4075-3. Epub 2015 Jan 29. Surg Endosc. 2015. PMID: 25631110 Free PMC article.
-
Long-Term Outcomes and Prognostic Factors in Periampullary Carcinoma.J Gastrointest Cancer. 2017 Mar;48(1):13-19. doi: 10.1007/s12029-016-9863-z. J Gastrointest Cancer. 2017. PMID: 27484980
-
Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma.Hum Pathol. 2013 Dec;44(12):2792-8. doi: 10.1016/j.humpath.2013.07.030. Epub 2013 Oct 15. Hum Pathol. 2013. PMID: 24139211 Free PMC article.
-
Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients.J Gastrointest Cancer. 2019 Sep;50(3):361-369. doi: 10.1007/s12029-018-0058-7. J Gastrointest Cancer. 2019. PMID: 29464529 Clinical Trial.
-
The road to tailored adjuvant chemotherapy for all four non-pancreatic periampullary cancers: An international multimethod cohort study.Br J Cancer. 2024 Jul;131(1):117-125. doi: 10.1038/s41416-024-02692-w. Epub 2024 May 28. Br J Cancer. 2024. PMID: 38806725 Free PMC article.
References
-
- Sarmiento JM, Nagomey DM, Sarr MG, Farnell MB. Periampullary cancers: are there differences? Surg Clin North Am. 2001;81(3):543–555. - PubMed
-
- Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg. 1991;161(1):120–124. discussion 124–5. - PubMed
-
- Androulakis J, Colborn GL, Skandalakis PN, et al. Embryologic and anatomic basis of duodenal surgery. Surg Clin North Am. 2000;80(1):171–199. - PubMed
-
- Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8–13. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical